Overview

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Status:
Completed
Trial end date:
2016-10-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis, specifically in improving signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Celgene Corporation
Treatments:
Apremilast
Thalidomide